Compare DexCom, Inc. (DXCM) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? DexCom, Inc. trades at $83.42 (market cap $31.86B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.8 (market cap $5.86B). The key difference: DexCom, Inc. is far larger — about 5.4× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and State Street SPDR Bloomberg High Yield Bond ETF for 60 Days on average.
| DXCM | JNK | |
|---|---|---|
Market Cap | $31.86B | $5.86B |
Volume | 3,607,070 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $98.02 |
52-Week Low | $54.84 | $92.30 |
Typical Hold Time | 62 Days | 60 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
JNK trades at $92.695 with a slight 0.07% decline, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.53 per share through mid-2026. Recent market focus centers on high-yield bond dynamics amid rising Treasury yields and institutional positioning changes.
The high-yield bond ETF faces headwinds from rising interest rates but benefits from institutional accumulation. Key risks include bond market volatility and economic sensitivity, while the consistent dividend stream provides income appeal for yield-seeking investors in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
